Atossa Therapeutics, Inc. (ATOS) NASDAQ

0.65

-0.0219(-3.25%)

Updated at April 01 04:00PM

Currency In USD

Atossa Therapeutics, Inc.

Address

107 Spring Street

Seattle, WA 98104

United States of America

Phone

206 588 0256

Sector

Healthcare

Industry

Biotechnology

Employees

15

First IPO Date

November 08, 2012

Key Executives

NameTitlePayYear Born
Dr. Steven C. Quay FCAP, M.D., Ph.D.Chairman, Chief Executive Officer & President1.27M1951
Dr. Richard Graydon M.D., Ph.D.Interim Chief Medical Officer0N/A
Mr. Michael ParksVice President of Investor & Public Relations0N/A
Ms. Delly Behen P.H.R.Senior Vice President of Administration & HR0N/A

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.